Business Context and Reporting Period
Company: PAVmed Inc. (PAVM)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: PAVmed is a diversified commercial-stage life sciences company operating in medical devices, diagnostics, and digital health. It utilizes a shared services model to support independently financed subsidiaries, including Lucid Diagnostics (cancer prevention diagnostics) and Veris Health (digital health and implantable monitors). The Company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $55 | $14 |
| Operating Loss | $(15,057) | $(10,160) |
| Net Loss Attributable to PAVmed | $(5,444) | $7,047 (Income) |
| Net Loss Attributable to Common Stockholders | $(12,467) | $4,386 (Income) |
| Cash and Cash Equivalents (End of Period) | $3,784 | $4,004 |
| Net Cash Used in Operating Activities | $(5,283) | $(2,759) |
| Total Debt (Senior Secured Convertible Notes) | $15,100 (Fair Value) | $11,100 (Fair Value) |
| Working Capital | $770 | $(12,280) |
Note: Revenue is primarily derived from the Veris Cancer Care Platform. The Company reported a net loss for the six months ended June 30, 2026, compared to net income in the prior year period, largely due to changes in fair value of investments and debt extinguishment losses.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased to $55,000 from $14,000 in the prior year six-month period, though absolute amounts remain minimal.
- Operating Expenses: Total operating expenses rose to $15.1 million from $10.2 million. General and Administrative (G&A) expenses increased by $2.9 million, driven by financing-related professional fees and stock-based compensation. R&D expenses increased by $1.9 million, primarily due to development of the Veris implantable physiological monitor.
- Debt Restructuring: The Company refinanced its September 2022 Senior Secured Convertible Note with a new "2026 Note" with a $15.0 million face value. This transaction resulted in a debt extinguishment loss of $3.4 million.
- Equity Transactions: The Company issued Series D Convertible Preferred Stock (subsequently converted to common stock) and redeemed all Series C Preferred Stock. A significant deemed dividend of $6.7 million was recognized related to the redemption of Series C Preferred Stock, impacting net income attributable to common stockholders.
- Investment Fair Value: The Company recognized an unrealized loss of $0.6 million on its equity method investment in Lucid Diagnostics, compared to an unrealized gain of $10.4 million in the prior year period.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern for one year following the issuance of the financial statements. This is due to recurring losses, negative operating cash flows, and the need for additional capital to fund operations and meet debt covenants.
- Debt Covenants: The 2026 Note includes a Minimum Cash Covenant requiring available cash of $2.5 million (increasing to $8.0 million after September 15, 2026). An amendment requires the Company to deposit $5 million in a blocked account by August 25, 2026, or the amendment becomes void.
- Unusual Items:
- Debt Extinguishment Loss: $3.4 million loss recognized in Q2 2026.
- Deemed Dividend: $6.7 million charge related to Series C Preferred Stock redemption.
- Stock-Based Compensation: Significant grants of restricted stock awards ($8.8 million aggregate fair value) to directors and officers in April 2026.
- Outlook: The Company expects to continue experiencing recurring losses and negative cash flows. Future operations depend on controlling costs, increasing revenue from the Veris platform, and raising additional capital through equity or debt financings.
Investor Verification Checklist
- Liquidity Status: Verify the Company's ability to meet the $5 million blocked account deposit requirement by August 25, 2026, to maintain compliance with the 2026 Note covenants.
- Capital Needs: Assess the timeline and likelihood of securing additional financing given the "substantial doubt" going concern disclosure.
- Revenue Sustainability: Evaluate the commercial traction of the Veris Cancer Care Platform, which generated only $55,000 in revenue for the six-month period.
- Debt Structure: Review the terms of the 2026 Note, including the 15% interest rate, conversion price ($450.00), and the potential for further dilution upon conversion.
- Equity Dilution: Monitor the impact of the recent conversion of Series D Preferred Stock (4.6 million shares) and outstanding warrants on future earnings per share.